FZD6 Targeting Identified as Key for Advanced Prostate Cancer Treatment

Researchers have identified FZD6 as a critical therapeutic target in advanced prostate cancer, revealing that its inhibition sensitizes cancer cells to specific kinase inhibitors. This discovery comes amid challenges associated with pan-Wnt signaling, which can lead to dose-limiting toxicities in patients. The findings suggest that targeting FZD6 may provide a more selective and effective treatment strategy.